Jesse Siffledeen

1.8k total citations · 1 hit paper
27 papers, 809 citations indexed

About

Jesse Siffledeen is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Jesse Siffledeen has authored 27 papers receiving a total of 809 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 17 papers in Epidemiology and 6 papers in Surgery. Recurrent topics in Jesse Siffledeen's work include Inflammatory Bowel Disease (19 papers), Microscopic Colitis (16 papers) and Vitamin D Research Studies (4 papers). Jesse Siffledeen is often cited by papers focused on Inflammatory Bowel Disease (19 papers), Microscopic Colitis (16 papers) and Vitamin D Research Studies (4 papers). Jesse Siffledeen collaborates with scholars based in Canada, United States and United Kingdom. Jesse Siffledeen's co-authors include Richard N. Fedorak, Kerry Siminoski, Gordon R. Greenberg, Hillary Steinhart, Ho Jen, Tim Card, Kate M. Fleming, Julián Panés, Peter Higgins and Stefan Schreiber and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and The American Journal of Gastroenterology.

In The Last Decade

Jesse Siffledeen

25 papers receiving 792 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis

2020 207 citations William J. Sandborn, Subrata Ghosh et al. Gastroenterology profile →

Peers

Countries citing papers authored by Jesse Siffledeen

Since Specialization

Citations

This map shows the geographic impact of Jesse Siffledeen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jesse Siffledeen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jesse Siffledeen more than expected).

Fields of papers citing papers by Jesse Siffledeen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jesse Siffledeen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jesse Siffledeen. The network helps show where Jesse Siffledeen may publish in the future.

Co-authorship network of co-authors of Jesse Siffledeen

This figure shows the co-authorship network connecting the top 25 collaborators of Jesse Siffledeen. A scholar is included among the top collaborators of Jesse Siffledeen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jesse Siffledeen. Jesse Siffledeen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Long-Term Effectiveness and Safety of Ustekinumab Dose Escalation in Patients with Moderate-to-Severe Ulcerative Colitis: A Multicenter Retrospective Cohort Study 2025 ·Digestive Diseases and Sciences ·(unknown), (unknown), (unknown), (unknown), Cathy Lu, Jesse Siffledeen, Karen I. Kroeker, Christopher Ma, Farhad Peerani, Brendan P. Halloran, Daniel C. Baumgart, Levinus A. Dieleman, Lillian Du, Frank Hoentjen, Karen K. Wong	1
2	Effect of Suboptimal Disease Control on Patient Quality of Life: Real-World Data from the Observational IBD-PODCAST Canada Trial 2024 ·Digestive Diseases and Sciences ·Jesse Siffledeen, Sunny Singh, (unknown), (unknown), (unknown), Claudia Leitner, (unknown), Laura E. Targownik	6
3	Upadacitinib Achieves Clinical and Endoscopic Outcomes in Crohn’s Disease Regardless of Prior Biologic Exposure 2024 ·Clinical Gastroenterology and Hepatology ·Laurent Peyrin‐Biroulet, Remo Panaccione, Édouard Louis, Raja Atreya, David T. Rubin, James O. Lindsay, Jesse Siffledeen, Dana J. Lukin, John Wright, Kenji Watanabe, (unknown), Valencia P. Remple, Ana P. Lacerda, Elena Dubcenco, (unknown), Qian Zhou, Sofie Berg, (unknown), Stefan Schreiber	8
4	OP16 Endoscopic and clinical outcomes of upadacitinib in patients with moderately to severely active Crohn’s disease by number and type of prior biologics 2023 ·Journal of Crohn s and Colitis ·Laurent Peyrin‐Biroulet, (unknown), (unknown), Jesse Siffledeen, (unknown), Efrat Broide, (unknown), Ana P. Lacerda, (unknown), (unknown), Sjoerd A.A. van den Berg, David T. Rubin	4
5	Tu1723 ENDOSCOPIC AND CLINICAL OUTCOMES OF UPADACITINIB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE BY NUMBER AND TYPE OF PRIOR BIOLOGICS 2023 ·Gastroenterology ·Laurent Peyrin‐Biroulet, Gareth Parkes, (unknown), Jesse Siffledeen, John Wright, Efrat Broide, (unknown), Ana P. Lacerda, (unknown), (unknown), Sofie Berg, David T. Rubin	1
6	Exploring Patient Perspectives on a 12-Week Online, Stress Reduction Intervention in Inflammatory Bowel Disease 2022 ·Crohn s & Colitis 360 ·Makayla Watt, Farhad Peerani, Karen Madsen, Jesse Siffledeen, Karen I. Kroeker, (unknown), Puneeta Tandon, (unknown)	2
7	A randomized controlled trial of a multicomponent online stress reduction intervention in inflammatory bowel disease 2022 ·Therapeutic Advances in Gastroenterology ·Farhad Peerani, Makayla Watt, Kathleen P. Ismond, Reid Whitlock, (unknown), Naomi Hotte, Nicholas Mitchell, Robert J. Bailey, Karen I. Kroeker, Levinus A. Dieleman, Jesse Siffledeen, (unknown), Karen Wong, Brendan P. Halloran, Daniel C. Baumgart, Lorian Taylor, Maitreyi Raman, Karen Madsen, Puneeta Tandon	20
8	OP24 Efficacy and safety of upadacitinib induction therapy in patients with Moderately to Severely Active Ulcerative Colitis: Results from the phase 3 U-ACHIEVE study 2021 ·Journal of Crohn s and Colitis ·Silvio Danese, Séverine Vermeire, Wen Zhou, Aileen L. Pangan, Jesse Siffledeen, Xavier Hébuterne, (unknown), Peter Higgins, (unknown), (unknown), B Huang, Wenhui Xie, (unknown), Michael Weinreich, (unknown)	15
9	Efficacy of Upadacitinib in a Randomized Trial of Patients With Active Ulcerative Colitis breakdown → 2020 ·Gastroenterology ·William J. Sandborn, Subrata Ghosh, Julián Panés, Stefan Schreiber, Geert D’Haens, Satoshi Tanida, Jesse Siffledeen, (unknown), Wen Zhou, Ahmed A. Othman, Bidan Huang, Peter Higgins	207
10	215 Efficacy and Safety of Upadacitinib as an Induction Therapy for Patients With Moderately-to-Severely Active Ulcerative Colitis: Combined Results From 382 Subjects in the Phase 2b Study U-ACHIEVE 2019 ·The American Journal of Gastroenterology ·Peter Higgins, Xavier Hébuterne, Jesse Siffledeen, Wen Zhou, Fabio Cataldi, Wangang Xie, Ana P. Lacerda, Silvio Danese	1
11	BioAdvance Patient Support Program Survey: Positive Perception of Intravenous Infusions of Infliximab. 2017 ·PubMed ·Jennifer Jones, Mark Borgaonkar, Jesse Siffledeen, (unknown), (unknown), Dorota Dajnowiec, Martin Williamson, (unknown)	2
12	Are IBD patients more likely to have a prior diagnosis of irritable bowel syndrome? Report of a case‐control study in the General Practice Research Database 2014 ·United European Gastroenterology Journal ·Tim Card, Jesse Siffledeen, Kate M. Fleming	40
13	An excess of prior irritable bowel syndrome diagnoses or treatments in Celiac disease: evidence of diagnostic delay 2013 ·Scandinavian Journal of Gastroenterology ·Tim Card, Jesse Siffledeen, Joe West, Kate M. Fleming	24
14	Urinary NMR metabolomic profiles discriminate inflammatory bowel disease from healthy 2012 ·Journal of Crohn s and Colitis ·(unknown), Jesse Siffledeen, (unknown), Travis B. Murdoch, Richard N. Fedorak, Carolyn M. Slupsky	95
15	Tu1301 Adult and Pediatric IBD Incidence in the UK: A Large Population-Based Study Using the General Practice Research Database 2012 ·Gastroenterology ·Jesse Siffledeen, Kate M. Fleming, Colin Crooks, Tim Card	0
16	Risedronate improves bone mineral density in Crohn's disease: A two year randomized controlled clinical trial 2012 ·Journal of Crohn s and Colitis ·(unknown), Jesse Siffledeen, Kerry Siminoski, (unknown), Richard N. Fedorak	13
17	Physician perspectives on unresolved issues in the use of conventional therapy in Crohn's disease: Results from an international survey and discussion programme 2011 ·Journal of Crohn s and Colitis ·Marc Ferrante, Konstantinos Κarmiris, Evan Newnham, Jesse Siffledeen, Zuzana Zelinková, Gert Van Assche, Péter L. Lakatos, Julián Panés, Andreas Sturm, Simon Travis, C. Janneke van der Woude, Walter Reinisch, Jean‐Frédéric Colombel, Remo Panaccione	13
18	Vertebral Fractures and Role of Low Bone Mineral Density in Crohn’s Disease 2007 ·Clinical Gastroenterology and Hepatology ·Jesse Siffledeen, Kerry Siminoski, Ho Jen, Richard N. Fedorak	35
19	Randomized trial of etidronate plus calcium and vitamin D for treatment of low bone mineral density in Crohn’s disease 2005 ·Clinical Gastroenterology and Hepatology ·Jesse Siffledeen, Richard N. Fedorak, Kerry Siminoski, Ho Jen, (unknown), Neena S. Abraham, Hillary Steinhart, Gordon R. Greenberg	57
20	Bones and Crohnʼs 2004 ·Inflammatory Bowel Diseases ·Jesse Siffledeen, Richard N. Fedorak, Kerry Siminoski, Ho Jen, (unknown), Neena S. Abraham, (unknown), Gordon R. Greenberg	67

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact